ArticleInternational journal of molecular sciences2022
Antidepressant Effect of Intermittent Long-Term Systemic Administration of Irisin in Mice.
Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Association between circulating irisin level and depression: a systematic review and meta-analysis.Annals of medicine · 2025Pooled it
- Association Between Irisin Level and Cognitive Function: A Systematic Review and Meta-Analysis.Brain and behavior · 2025Pooled it
- Irisin treatment counteracts bone loss and muscle atrophy in aged mice by reducing sclerostin expression in bone and skeletal muscle.Journal of translational medicine · 2026Article
- Changes in Sarcopenia and Incident Depression in Prospective Cohorts.Journal of clinical medicine · 2026Article
- Physical activity during COVID-19 pandemic: A 5-year retrospect.Sports medicine and health science · 2025Review
- Irisin, the Myokine: Guardian and Mediator in Cardiovascular System.Endocrinology, diabetes & metabolism · 2025Review
- Comparative psychological well-being evaluation among CKD patients on conservative therapy, dialysis, or kidney transplantation: a cross-sectional study.Frontiers in psychology · 2025Article
- The Dual Role of Myokines in Fatigue Associated with Inflammatory Joint Diseases.Journal of inflammation research · 2025Review
- Irisin prevents trabecular bone damage and tumor invasion in a mouse model of multiple myeloma.JBMR plus · 2024Article
- The role of exercise-related FNDC5/irisin in depression.Frontiers in pharmacology · 2024Review
- Exercise for Mental Well-Being: Exploring Neurobiological Advances and Intervention Effects in Depression.Life (Basel, Switzerland) · 2023Review
- Move Your Body, Boost Your Brain: The Positive Impact of Physical Activity on Cognition across All Age Groups.Biomedicines · 2023Review
- Irisin Protects against Loss of Trabecular Bone Mass and Strength in Adult Ovariectomized Mice by Stimulating Osteoblast Activity.International journal of molecular sciences · 2023Article
- Short-Term Irisin Treatment Enhanced Neurotrophin Expression Differently in the Hippocampus and the Prefrontal Cortex of Young Mice.International journal of molecular sciences · 2023Article
- Once-Daily Subcutaneous Irisin Administration Mitigates Depression- and Anxiety-like Behavior in Young Mice.International journal of molecular sciences · 2023Article
- Antidepressant Activities of Synthesized Benzodiazepine Analogues in Mice.Brain sciences · 2023Article
- Investigation of Antistress and Antidepressant Activities of Synthetic Curcumin Analogues: Behavioral and Biomarker Approach.Biomedicines · 2022Article
- From rodents to humans: Rodent behavioral paradigms for social behavioral disorders.Brain circulationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
Depression is a psychiatric disorder increasingly diffused worldwide. Evidence suggests that irisin, a myokine secreted by contracting muscle, mediates beneficial effects on several targets, including the brain. Here, the potential antidepressant properties of long-term intermittent systemic irisin administration (100 µg/kg/weekly for 1 month) were evaluated in mice by the Tail Suspension Test (TST), Forced Swim Test (FST), and Open Field Test (OFT). Furthermore, to deepen the molecular pathways underlying irisin treatment, the expression of irisin precursor, neurotrophic/growth factors, and cytokines was analyzed. Irisin treatment significantly decreased the immobility time in the TST and FST, suggesting an antidepressant effect. Additionally, irisin seemed to display an anxiolytic-like effect increasing the time spent in the OFT arena center. These findings were probably due to the modulation of endogenous brain factors as the gene expression of some neurotrophins, such as brain-derived neurotrophic factor (BDNF) and insulin-like growth factor (IGF-1), was upregulated only in irisin-treated mouse brain. Moreover, irisin modulated the expression of some cytokines (IL-1β, IL-4, IL-6, and IL-10). To the best of our knowledge, this is the first study demonstrating that the irisin antidepressant effect may be observed even with a systemic administration in mice. This could pave the way toward intriguing preclinical research in humans.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.